JP2016514117A - ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアシルアミノシクロアルキル化合物 - Google Patents
ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアシルアミノシクロアルキル化合物 Download PDFInfo
- Publication number
- JP2016514117A JP2016514117A JP2015562180A JP2015562180A JP2016514117A JP 2016514117 A JP2016514117 A JP 2016514117A JP 2015562180 A JP2015562180 A JP 2015562180A JP 2015562180 A JP2015562180 A JP 2015562180A JP 2016514117 A JP2016514117 A JP 2016514117A
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- butyl
- tert
- piperazin
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)(*)c1nc(C2CCC2)cc(N2CCN(CC[C@]3CC[C@](*)CC3)CC2)n1 Chemical compound CC(C)(*)c1nc(C2CCC2)cc(N2CCN(CC[C@]3CC[C@](*)CC3)CC2)n1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786869P | 2013-03-15 | 2013-03-15 | |
| US61/786,869 | 2013-03-15 | ||
| US201361918524P | 2013-12-19 | 2013-12-19 | |
| US61/918,524 | 2013-12-19 | ||
| PCT/EP2014/055062 WO2014140246A1 (en) | 2013-03-15 | 2014-03-14 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016514117A true JP2016514117A (ja) | 2016-05-19 |
| JP2016514117A5 JP2016514117A5 (enExample) | 2017-04-06 |
Family
ID=50280387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562180A Pending JP2016514117A (ja) | 2013-03-15 | 2014-03-14 | ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアシルアミノシクロアルキル化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9388148B2 (enExample) |
| EP (1) | EP2970146B1 (enExample) |
| JP (1) | JP2016514117A (enExample) |
| CN (1) | CN105339357A (enExample) |
| AU (1) | AU2014230215A1 (enExample) |
| BR (1) | BR112015021471A2 (enExample) |
| CA (1) | CA2902656A1 (enExample) |
| MX (1) | MX2015012184A (enExample) |
| TW (1) | TW201514154A (enExample) |
| UY (1) | UY35420A (enExample) |
| WO (1) | WO2014140246A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022554130A (ja) * | 2019-10-29 | 2022-12-28 | 上▲海▼翰森生物医▲薬▼科技有限公司 | 四員環誘導体の調節剤、調製方法及びその利用 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| AR095264A1 (es) * | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
| US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
| CA3089498A1 (en) | 2018-01-26 | 2019-08-01 | Shionogi & Co., Ltd. | Condensed ring compounds having dopamine d3 receptor antagonistic effect |
| WO2020156312A1 (zh) * | 2019-01-30 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
| CN112239433B (zh) * | 2019-07-17 | 2024-05-14 | 北京盈科瑞创新药物研究有限公司 | 一种环己烷衍生物、制备方法及其应用 |
| TWI873212B (zh) * | 2019-10-29 | 2025-02-21 | 大陸商上海翰森生物醫藥科技有限公司 | 四員環類衍生物調節劑、其製備方法和應用 |
| CN113754580B (zh) | 2020-06-05 | 2023-04-25 | 上海中泽医药科技有限公司 | 一种吡啶吗啉类化合物、其制备方法及其应用 |
| TW202302576A (zh) * | 2021-04-28 | 2023-01-16 | 大陸商上海翰森生物醫藥科技有限公司 | 含哌嗪多環類衍生物的鹽及晶型及其製備方法和應用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007148208A2 (en) * | 2006-06-22 | 2007-12-27 | Bioprojet | Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands |
| WO2011161009A1 (en) * | 2010-06-21 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anellated pyridine compounds as dual modulators of the 5-ht2a and d3 receptors |
| JP2012502944A (ja) * | 2008-09-22 | 2012-02-02 | エフ．ホフマン−ラ ロシュ アーゲー | ピペラジンｄ３及び５−ｈｔ２ａ受容体調節薬 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10311065A1 (de) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
| JP2004359689A (ja) | 2003-06-05 | 2004-12-24 | Abbott Gmbh & Co Kg | ドーパミンｄ３受容体のモジュレーションに反応する障害の治療に適するトリアゾール化合物 |
| DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| DE102004027359A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
| ES2340941T3 (es) | 2004-08-09 | 2010-06-11 | ABBOTT GMBH & CO. KG | Compuestos de 4-piperazinil-pirimidina adecuados para tretar trastornos que responden a modulacion del receptor d 3 de dopamina. |
| DE102004061593A1 (de) * | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung |
| HUP0500170A3 (en) | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| CA2691082A1 (en) | 2007-07-02 | 2009-01-08 | F. Hoffmann-La Roche Ag | 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) |
| PA8802101A1 (es) | 2007-11-02 | 2009-08-26 | Abbott Gmbh & Co Kg | Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 |
| US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| AU2009296047A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyridinylpiperazin derivatives useful as modulators of dopamine D3 receptors |
| US8470828B2 (en) | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
-
2014
- 2014-03-13 UY UY0001035420A patent/UY35420A/es not_active Application Discontinuation
- 2014-03-14 JP JP2015562180A patent/JP2016514117A/ja active Pending
- 2014-03-14 MX MX2015012184A patent/MX2015012184A/es unknown
- 2014-03-14 EP EP14710261.0A patent/EP2970146B1/en active Active
- 2014-03-14 BR BR112015021471A patent/BR112015021471A2/pt not_active IP Right Cessation
- 2014-03-14 AU AU2014230215A patent/AU2014230215A1/en not_active Abandoned
- 2014-03-14 CA CA2902656A patent/CA2902656A1/en not_active Abandoned
- 2014-03-14 CN CN201480026453.XA patent/CN105339357A/zh active Pending
- 2014-03-14 TW TW103109325A patent/TW201514154A/zh unknown
- 2014-03-14 US US14/213,169 patent/US9388148B2/en active Active
- 2014-03-14 WO PCT/EP2014/055062 patent/WO2014140246A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007148208A2 (en) * | 2006-06-22 | 2007-12-27 | Bioprojet | Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands |
| JP2012502944A (ja) * | 2008-09-22 | 2012-02-02 | エフ．ホフマン−ラ ロシュ アーゲー | ピペラジンｄ３及び５−ｈｔ２ａ受容体調節薬 |
| WO2011161009A1 (en) * | 2010-06-21 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anellated pyridine compounds as dual modulators of the 5-ht2a and d3 receptors |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022554130A (ja) * | 2019-10-29 | 2022-12-28 | 上▲海▼翰森生物医▲薬▼科技有限公司 | 四員環誘導体の調節剤、調製方法及びその利用 |
| JP7783174B2 (ja) | 2019-10-29 | 2025-12-09 | 上▲海▼翰森生物医▲薬▼科技有限公司 | 四員環誘導体の調節剤、調製方法及びその利用 |
| KR102982614B1 (ko) * | 2019-10-29 | 2026-06-26 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 4원 고리 유도체의 개질제, 및 이의 제조 방법 및 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014140246A1 (en) | 2014-09-18 |
| BR112015021471A2 (pt) | 2017-07-18 |
| EP2970146B1 (en) | 2017-11-01 |
| TW201514154A (zh) | 2015-04-16 |
| CN105339357A (zh) | 2016-02-17 |
| AU2014230215A1 (en) | 2015-09-03 |
| CA2902656A1 (en) | 2014-09-18 |
| US9388148B2 (en) | 2016-07-12 |
| US20140303176A1 (en) | 2014-10-09 |
| UY35420A (es) | 2014-10-31 |
| EP2970146A1 (en) | 2016-01-20 |
| MX2015012184A (es) | 2016-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2970146B1 (en) | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor | |
| US9376396B2 (en) | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | |
| AU2007251553A1 (en) | 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors | |
| JP2008536824A (ja) | ヒスタミンｈ３受容体薬剤、製剤及び治療的使用 | |
| JP2020504122A (ja) | ヘテロアリール化合物およびその使用 | |
| US6919342B2 (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| RU2478633C2 (ru) | Производные 1,2,4-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3 | |
| EP1484330B1 (en) | Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| US9388141B2 (en) | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | |
| EP2203426B9 (en) | Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor | |
| EP3442966B1 (en) | Novel n-[(pyrimidinylamino)propanyl]- and n-[(pyridinylamino)propanyl]arylcarboxamides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170306 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170306 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180313 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20181016 |